Sugi Predict

Sugi Predict / Compounds / SCHEMBL460228

SCHEMBL460228

SCHEMBL460228

C=C(N)COC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 1/20 0.66
▸ CCNB1 P14635 1/20 0.66
▸ CA2 P00918 2/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ LDHA P00338 1/20 0.39
▸ ADORA1 P30542 1/20 0.38
▸ EPHX2 P34913 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SLC6A2 P23975 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ TYR P14679 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SYNJ2 O15056 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28105422 0.89 CDK1 (0.66) CDK1CCNB1CA2CA9LDHA
SCHEMBL3400935 0.87 CDK1 (0.64) CDK1CCNB1CA2CA9LDHA
SCHEMBL460227 0.86 CDK1 (0.56) CDK1CCNB1CA2CA9LDHA
SCHEMBL27801162 0.86 CDK1 (0.72) CDK1CCNB1CA2CA9LDHA
SCHEMBL27877094 0.86 CDK1 (0.75) CDK1CCNB1CA2CA9LDHA
SCHEMBL4623411 0.85 CDK1 (0.67) CDK1CCNB1CA2CA9LDHA
SCHEMBL29287549 0.84 CDK1 (0.66) CDK1CCNB1CA2CA9LDHA
SCHEMBL3507329 0.84 CDK1 (0.66) CDK1CCNB1CA2CA9LDHA
SCHEMBL27548559 0.83 CDK1 (0.72) CDK1CCNB1CA2CA9LDHA
SCHEMBL108212 0.83 CDK1 (0.72) CDK1CCNB1CA2CA9LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524510-B2 Alkyl-glycoside enhanced vaccination THE UAB RESEARCH FOUNDATION (US) 2009-04-28 — — US claimed
CN-101163494-A Alkyl-glycoside enhanced vaccination UAB RESEARCH FOUNDATION (US) 2008-04-16 — — CN claimed
EP-1863511-A2 ALKYL-GLYCOSIDE ENHANCED VACCINATION UAB Research Foundation (US) 2007-12-12 — — EP claimed
US-20060233761-A1 Noninvasive immunization; immunostimulants UAB RESEARCH FOUNDATION, THE 2006-10-19 — — US claimed
WO-2006091722-A2 ALKYL-GLYCOSIDE ENHANCED VACCINATION UAB RESEARCH FOUNDATION (US) 2006-08-31 — — WO claimed
US-20240197719-A1 FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE AEGIS THERAPEUTICS, LLC (US) 2024-06-20 — — US disclosed
US-11969501-B2 Auris formulations for treating otic diseases and conditions DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-04-30 — — US disclosed
EP-3328898-B1 TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS OTONOMY INC (US) 2024-03-06 — — EP disclosed
US-11918653-B2 Triglyceride otic formulations and uses thereof DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-03-05 — — US disclosed
US-11918655-B2 Intranasal epinephrine formulations and methods for the treatment of disease AEGIS THERAPEUTICS, LLC (US) 2024-03-05 — — US disclosed
US-20240066028-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS PFIZER IRELAND PHARMACEUTICALS (IE) 2024-02-29 — — US disclosed
US-20240041983-A1 IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS CYPRUMED GMBH (AT) 2024-02-08 — — US disclosed
US-20060045868-A1 Absorption enhancers for drug administration AEGIS THERAPEUTICS LLC 2006-03-02 — — US disclosed
US-20060046962-A1 Absorption enhancers for drug administration AEGIS THERAPEUTICS LLC (US) 2006-03-02 — — US disclosed
US-20060046969-A1 Antibacterial compositions for drug administration AEGIS THERAPEUTICS LLC (US) 2006-03-02 — — US disclosed
US-20060045869-A1 Absorption enhancers for drug administration AEGIS THERAPEUTICS LLC 2006-03-02 — — US disclosed
US-5817634-A Methods of treating diabetes mellitus and clycogen storage disease THE UAB RESEARCH FOUNDATION (US) 1998-10-06 — — US disclosed
US-5661130-A NONTOXIC, NONIONIC ALKYL GLYCOSIDE HAVING A HYDROPHOBIC ALKYL JOINED BY A LINKAGE TO A HYDROPHILIC SACCHARIDE THE UAB RESEARCH FOUNDATION (US) 1997-08-26 — — US disclosed
US-5384128-A Method of and compounds for treatment for cystic fibrosis UNIVERSITY OF ALABAMA RESEARCH FOUNDATION (US) 1995-01-24 — — US disclosed
WO-1995000151-A1 ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION UAB RESEARCH FOUNDATION (US) 1995-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11918655-B2 Intranasal epinephrine formulations and methods for the treatment of disease ADRA2C, ADRA2A, ADRB2 CDK1 4857/4885CCNB1 4816/4885CA2 4062/4885
US-20240041983-A1 IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS GLP1R, GIPR, GCGR CDK1 3104/4885CCNB1 3292/4885CA2 1526/4885
US-20240066028-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS CALCB, CALCA, CALCRL CDK1 4084/4885CCNB1 2905/4885CA2 2407/4885
US-20240197719-A1 FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE OPRK1, OPRM1, OGFR CDK1 4496/4885CCNB1 4624/4885CA2 4303/4885
US-11918653-B2 Triglyceride otic formulations and uses thereof CETP, LIPA, APOB CDK1 4878/4885CCNB1 4692/4885CA2 4522/4885
US-11969501-B2 Auris formulations for treating otic diseases and conditions OTC, AQP4, SLC26A4 CDK1 3532/4885CCNB1 4200/4885CA2 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.